{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:11:58Z","timestamp":1781712718030,"version":"3.54.5"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Doxorubicin- and epirubicin-induced cardiotoxicities are life threatening for those suffering from breast cancer. Comparing the effects of different strategies on the prevention of these agent-induced cardiotoxicities remains unexplored.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Data sources:<\/jats:bold>\n                      A comprehensive review of clinical trials was performed on the prevention of epirubicin- and\/or doxorubicin-induced cardiotoxicity in HER2-positive metastatic breast cancer patients. The reduction in ejection fraction was directed at evaluating cardiac toxicity.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Data summary:<\/jats:bold>\n                      Fourteen articles evaluated cardiotoxicity as a condition among 2945 individuals, evaluating doxorubicin, epirubicin, Liposomal Doxorubicin (LD), Pegylated Liposomal Doxorubicin (PLD), dexrazoxane plus doxorubicin or epirubicin, and Angiotensin-Converting Enzyme Inhibitors (ACEIs) plus doxorubicin. Pooled Odds Ratio (OR) of 0.043 with a 95% credible interval (CrI) between 0.005 and 0.22 indicated that the dexrazoxane plus epirubicin reduced the number of cardiac events compared with doxorubicin. Furthermore, doxorubicin and epirubicin represented the most effective interventions with a 52% probability of success. Also, the best treatment for reducing Congestive Heart Failure (CHF) was dexrazoxane plus epirubicin with a probability of 43%. For the Left Ventricular Ejection Fraction (LVEF) reduction outcome, ACEIs plus doxorubicin was ranked first with a success probability of 61.2% and they could significantly prevent the reduction in LVEF compared with LD, epirubicin, or doxorubicin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggested that angiotensin-converting enzyme inhibitors and dexrazoxane plus epirubicin were the most effective interventions for preventing cardiotoxicity and CHF. However, ACEIs plus doxorubicin was the best treatment for preventing LVEF reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220965674","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T03:26:47Z","timestamp":1603250807000},"page":"414-427","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-0231","authenticated-orcid":false,"given":"Khojasteh","family":"Ghasemi","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Student Research Committee, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Vaseghi","sequence":"additional","affiliation":[{"name":"Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-0282","authenticated-orcid":false,"given":"Marjan","family":"Mansourian","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel RL","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: 2017; 67: 7\u201330.","journal-title":"CA:"},{"key":"e_1_3_4_3_2","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw PT","year":"2016","unstructured":"Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology (Cambridge, Mass) 2016; 27: 6--13.","journal-title":"Epidemiology (Cambridge, Mass"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175544"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2919"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01262"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058421"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S170239"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2003.08.005"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-019-0736-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_4_13_2","unstructured":"RevMan R. The nordic Cochrane Centre the Cochrane collaboration. Book [computer program]. version https:\/\/community.cochrane.org\/help\/tools-and-software\/revman-5 (2014 accessed 9 July 2014)."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624010-00001"},{"key":"e_1_3_4_15_2","unstructured":"van Valkenhoef G Kuiper J. GeMTC: network meta-analysis using bayesian methods. R package version 0.8-1. http:\/\/github.com\/gertvv\/gemtc (2016 accessed 23 December 2016)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099682"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1177011136"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1113-0"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.6.976"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","unstructured":"Batist G Ramakrishnan G Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. 2001. 19: 1444\u20131454.","DOI":"10.1200\/JCO.2001.19.5.1444"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.635144"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh393"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.4.679"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","unstructured":"Harris L Batist G Belt R et al. Liposome\u2010encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first\u2010line therapy of metastatic breast carcinoma. 2002; 94: 25\u201336.","DOI":"10.1002\/cncr.10201"},{"key":"e_1_3_4_29_2","article-title":"Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy","author":"Huang G","year":"2018","unstructured":"Huang G, Zhai J, Huang X, et al. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine 2018; 97: e12447. DOI: 10.1097\/MD.0000000000012447.","journal-title":"Medicine"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.6.818"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.86"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj134"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","unstructured":"O'Brien ME Wigler N Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology 2004; 15: 440--449.","DOI":"10.1093\/annonc\/mdh097"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.117"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1318"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.12.3112"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-337"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.031"},{"key":"e_1_3_4_39_2","unstructured":"Iqbal M Dubey K Anwer T et al. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports 2008; 60: 382--390."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0802-4"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw671"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000500204"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220965674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220965674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220965674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:59Z","timestamp":1777688639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220965674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1078155220965674"],"URL":"https:\/\/doi.org\/10.1177\/1078155220965674","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]}}}